Physician profile
Priya Velappan Kumar
NPI 1427189935
$4,611.44
in general payments reported to CMS, 2019-2025
30 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $240 · 2021: $666 · 2022: $640 · 2023: $347 · 2024: $613 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $932.61 | 2019-2025 | Diamondback Coronary, Xience Skypoint, Cardiomems |
| Edwards Lifesciences Corporation | $669.97 | 2019-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $482.47 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Progrip |
| Inari Medical, INC. | $380.86 | 2021-2022 | |
| Abiomed | $317.22 | 2019-2023 | Impella |
| Medtronic Vascular, INC. | $295.95 | 2019-2020 | |
| Cardiovascular Systems INC. | $241.25 | 2019-2023 | Diamondback Coronary |
| Astrazeneca Pharmaceuticals LP | $166.53 | 2019-2024 | |
| Boston Scientific Corporation | $116.37 | 2020-2025 | Eluvia, Farapulse |
| Biosense Webster, INC. | $108.46 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $107.55 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.34 | 2019-2023 | Lifevest |
| Impulse Dynamics (USA) INC. | $90.15 | 2021 | |
| Ge Healthcare | $86.81 | 2019-2021 | |
| Amgen INC. | $78.79 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $77.55 | 2024 | |
| Cvrx, INC. | $66.10 | 2023-2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $44.41 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $42.53 | 2019 | |
| Csl Behring | $40.60 | 2019 | |
| Atricure, INC. | $38.81 | 2023 | |
| Sanofi-Aventis U.S. LLC | $35.07 | 2019 | |
| Recor Medical INC | $25.48 | 2024 | Paradise Renal Denervation System |
| Shockwave Medical, INC | $23.53 | 2022 | |
| Philips North America LLC | $19.72 | 2025 | Azurion 7 M20 |
| Glaxosmithkline, LLC. | $18.37 | 2023 | Shingrix |
| Pfizer INC. | $10.94 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.